真的只是小刺一下吗?季节性流感疫苗接种随机对照试验安慰剂对照组不良事件的荟萃分析
该荟萃分析检索PubMed、Web of Science和CENTRAL并考虑灰色文献,纳入31项含药理学惰性安慰剂组的随机对照试验、共14,326名安慰剂组参与者,评估季节性流感疫苗接种试验中安慰剂组报告的不良事件效应量。结果显示安慰剂组报告了显著的征集性不良事件比例效应量,提示接种后存在实质性反安慰剂效应。
要点
- 13个安慰剂组中35%的参与者报告至少一种征集性全身不良事件(p=0.007)。
- 最常见的征集性全身不良事件为头痛(27组;17%;p=0.001)、不适(13组;12%;p=0.004)和多汗(4组;12%;p<0.001)。
- 作者认为卫生保健人员应认识到反安慰剂反应并采取措施预防或减轻免疫接种后不良事件负担。
核心结论
- 安慰剂组报告了显著的征集性不良事件,表明接种后存在实质性反安慰剂效应。
- 作者基于多数疫苗接种规划纳入相似健康人群的事实,预期其他接种活动中会出现可比的反安慰剂效应。
- 作者认为卫生保健人员应认识到反安慰剂反应并采取措施预防或减轻免疫接种后不良事件负担,且应尽早处理对副作用的恐惧以减少疫苗犹豫。
研究设计与样本
- 通过PubMed、Web of Science和CENTRAL进行文献检索,并考虑灰色文献。
- 仅纳入安慰剂组使用药理学惰性物质(如生理盐水)的随机对照试验。
- 使用Cochrane协作网偏倚风险工具评估质量,基于k=31项研究、14,326名安慰剂组参与者,采用随机混合效应模型估计效应量。
主要发现
- 在k=13个分析的安慰剂组中,35%的参与者报告至少一种征集性全身不良事件(p=0.007)。
- 最常见的特定征集性全身不良事件为接种后一周内头痛(k=27;17%;p=0.001)。
- 接种后一周内不适为(k=13;12%;p=0.004),多汗为(k=4;12%;p<0.001)。
关键数值与推荐
- 安慰剂组至少一种征集性全身不良事件比例:35%(k=13;p=0.007)。
- 头痛:17%(k=27;p=0.001);不适:12%(k=13;p=0.004);多汗:12%(k=4;p<0.001)。
临床怎么用
- 作者认为卫生保健人员应认识到反安慰剂反应并采取措施预防或减轻免疫接种后不良事件负担。
- 作者认为应尽早处理对副作用的恐惧以减少疫苗犹豫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Corona pandemic and ongoing mass vaccinations raise the question of the nocebo mechanisms involved. Since immunization is usually administered to healthy people as a preventive health measure, adverse events (AE) following immunization are less accepted and could contribute to vaccine hesitancy. Assuming that vaccinees experience nocebo responses, the aim of this meta-analysis was to investigate the effect sizes of solicited adverse events (or assumed reactogenicity) reported in placebo groups in RCTs on seasonal influenza vaccination. METHODS: Literature search via PubMed, Web of Science, and CENTRAL was conducted considering gray literature. Only RCTs with placebo groups using pharmacologically inert substances (like saline) were included. Quality was assessed using Cochrane Collaboration's Risk of Bias Tool. Effect sizes were estimated using a random mixed effects model based on k = 31 studies covering 14,326 participants in placebo groups. RESULTS: Reported solicited AEs in placebo groups showed significant effect sizes of proportions (ESp). In k = 13 analyzed placebo groups, 35 % of the participants reported at least one solicited systemic AE (p = 0.007). The most common particular solicited systemic AEs were headache (k = 27; 17 %; p = 0.001), malaise (k = 13; 12 %; p = 0.004), and hyperhidrosis (k = 4; 12 %; p < 0.001) within one week after vaccination. CONCLUSION: The results show significant solicited AEs in placebo groups, indicating substantial nocebo responses after vaccination. Based on the fact that most vaccination programs include similar groups of healthy people, we expect that comparable nocebo effects occur during other campaigns. Health care professionals should be aware of the nocebo response and take action to prevent or decrease the burden of adverse events following immunization. Fear of side effects must be addressed early in order to diminish vaccine hesitancy. Prospero identifier: CRD42020156287, October 2019.
引用
- Bender FL, Rief W, Wilhelm M, et al. Really just a little prick? A meta-analysis on adverse events in placebo control groups of seasonal influenza vaccination RCTs. Vaccine. 2022. PMID: 36464541. doi:10.1016/j.vaccine.2022.11.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。